Calcium gluconate

Identification

Name
Calcium gluconate
Accession Number
DB11126
Type
Small Molecule
Groups
Approved, Vet approved
Description

Calcium gluconate is a mineral supplement and medication. Supplementation is generally only required when there is not enough calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only. Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate. Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.

Structure
Thumb
Synonyms
  • Calcarea gluconica
  • Calcii gluconas
  • Calcium di-gluconate
  • Calcium gluconate anhydrous
  • Calcium gluconate, anhydrous
  • D-gluconic acid, calcium salt (2:1)
External IDs
E-578 / INS NO.578 / INS-578
Product Ingredients
IngredientUNIICASInChI Key
Calcium gluconate monohydrateCZN0MI5R3166905-23-5XLNFVCRGJZBQGX-XRDLMGPZSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium GluconateInjection, solution98 mg/mLIntravenousGeneral Injectables & Vaccines2018-02-12Not applicableUs
Calcium GluconateInjection, solution98 mg/mLIntravenousFresenius Kabi2017-06-15Not applicableUs
Calcium Gluconate 10% Inj 100mg/mlLiquid100 mgIntravenousAstra Zeneca1986-12-312004-11-01Canada
Calcium Gluconate Inj 10%Solution100 mgIntravenousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Calcium Gluconate Inj 100mg/mlSolution100 mgIntramuscular; IntravenousHospira, Inc.1981-12-312010-11-05Canada
Calcium Gluconate Inj USP 10%Solution.465 meqIntravenousInternational Medication Systems, Limited1985-12-311997-08-15Canada
Calcium Gluconate Injection USPSolution94 mgIntravenousSandoz Canada Incorporated1990-12-312010-11-17Canada
Exchange Transfusion Tray 10%Liquid10 %IntravenousBaxter Laboratories1992-12-311999-08-10Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Gluconate Tab 600mgTablet600 mgOralSwiss Herbal Remedies Ltd.1983-12-312003-09-10Canada
Calcium Gluconate Tab 648mgTablet648 mgOralHall Laboratories, Ltd.1981-12-312003-09-11Canada
Calcium Gluconate Tab 648mgTablet648 mgOralPharmetics (2011) Inc.1973-12-312000-08-21Canada
Calcium Gluconate Tab 648mg USPTablet648 mgOralLab Gernetic Int Ltee1985-12-311997-02-21Canada
Calcium Gluconate Tab 650mgTablet650 mgOralVita Health Products Inc1972-12-312002-07-31Canada
Calcium Gluconate Tab 650mgTablet650 mgOralShoppers Drug Mart Inc.1978-12-311997-08-15Canada
Calcium Gluconate Tab 650mgTablet650 mgOralD.C. Labs Limited1969-12-312005-07-19Canada
Calcium Gluconate Tab 650mgTablet650 mgOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1979-12-311996-09-09Canada
Calcium Gluconate Tablets 648mg USPTablet648 mgOralVita Health Products Inc1988-12-312002-07-31Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium Gluconate Injection, USP 10%Calcium gluconate (94 mg) + Calcium saccharate (4.5 mg)SolutionIntravenousFresenius Kabi1984-07-19Not applicableCanada
Calcium LiquidCalcium gluconate (112 mg) + Calcium Gluceptate (132 mg)LiquidOralKsl Pharmaceuticals1994-12-311996-09-09Canada
Calcium LiquidCalcium gluconate (112 mg) + Calcium Gluceptate (132 mg)LiquidOralShoppers Drug Mart Inc.1981-12-311997-08-15Canada
Calcium LiquidCalcium gluconate (112 mg) + Calcium Gluceptate (132 mg)LiquidOralVita Health Products Inc1980-12-312002-07-31Canada
Calcium Magnesium Plus Vitamin D LiquidCalcium gluconate (6 mg) + Ergocalciferol (2 unit) + Inositol nicotinate (.6 mg) + Magnesium citrate (3 mg)LiquidOralJamp Pharma Corporation2002-04-222003-02-05Canada
Dicalcine Tab No460Calcium gluconate (155 mg) + Calcium lactate (155 mg)TabletOralHerbes Universelles Inc.1976-12-312009-07-15Canada
Liquid CalciumCalcium gluconate (112 mg) + Calcium Gluceptate (132 mg)LiquidOralWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.1998-08-122000-07-06Canada
Multiple Electrolyte Additive InjCalcium gluconate (20.6 mg) + Magnesium sulfate (19.8 mg) + Potassium Chloride (29.8 mg) + Sodium Chloride (46.6 mg)LiquidIntravenousInternational Medication Systems, Limited1980-12-311997-08-15Canada
Proception Sperm Nutrient DoucheCalcium gluconate (2.55 %) + Glucose (71 %) + Potassium Chloride (.7 %) + Sodium Chloride (25.75 %)DoucheVaginalMilex Products Ltd.1951-12-311997-07-16Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium GluconateCalcium gluconate monohydrate (.465 meq/mL)Injection, solutionIntravenousGeneral Injectables & Vaccines2010-04-012017-02-02Us
Calcium GluconateCalcium gluconate monohydrate (98 mg/mL)Injection, solutionIntravenousAmerican Regent1990-09-30Not applicableUs
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousRemedy Repack2015-10-082018-01-06Us
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousRemedy Repack2015-03-162017-04-14Us
Calcium GluconateCalcium gluconate monohydrate (98 mg/mL)Injection, solutionIntravenousAmerican Regent1992-12-01Not applicableUs
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousRemedy Repack2015-06-192017-07-27Us
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousCardinal Health2000-08-092017-08-03Us
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousFresenius Kabi2000-07-12Not applicableUs
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousGeneral Injectables & Vaccines2010-08-012018-02-27Us
Calcium GluconateCalcium gluconate (94 mg/mL)Injection, solutionIntravenousA S Medication Solutions2000-08-092017-06-20Us
Categories
UNII
SQE6VB453K
CAS number
299-28-5
Weight
Average: 430.372
Monoisotopic: 430.0635463
Chemical Formula
C12H22CaO14
InChI Key
NEEHYRZPVYRGPP-IYEMJOQQSA-L
InChI
InChI=1S/2C6H12O7.Ca/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1
IUPAC Name
calcium bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)
SMILES
[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O

Pharmacology

Indication

Oral calcium salts are used as dietary supplemental therapy for person who may not get enough calcium in their regular diet. Calcium gluconate is used as a cardioprotective agent in high blood potassium. Calcium gluconate is the antidote for magnesium sulfate toxicity.

Associated Conditions
Pharmacodynamics

Calcium Gluconate is the gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers.

Mechanism of action

Calcium is essential for the functional integrity of the nervous, muscular, and skeletal systems. It plays a role in normal cardiac function, renal function, respiration, blood coagulation, and cell membrane and capillary permeability. Also, calcium helps to regulate the release and storage of neurotransmitters and hormones, the uptake and binding of amino acids, absorption of vitamin B 12, and gastrin secretion. The major fraction (99%) of calcium is in the skeletal structure primarily as hydroxyapatite, Ca 10(PO 4) 6(OH) 2; small amounts of calcium carbonate and amorphous calcium phosphates are also present. The calcium of bone is in a constant exchange with the calcium of plasma. Since the metabolic functions of calcium are essential for life, when there is a disturbance in the calcium balance because of dietary deficiency or other causes, the stores of calcium in bone may be depleted to fill the body's more acute needs. Therefore, on a chronic basis, normal mineralization of bone depends on adequate amounts of total body calcium.

Absorption

Approximately one-fifth to one-third of orally administered calcium is absorbed in the small intestine, depending on presence of vitamin D metabolites, pH in lumen, and on dietary factors, such as calcium binding to fiber or phytates. Calcium absorption is increased when a calcium deficiency is present or when a patient is on a low-calcium diet. In patients with achlorhydria or hypochlorhydria, calcium absorption, especially with the carbonate salt, may be reduced.

Volume of distribution

Not available

Protein binding

Moderate, approximately 45% in plasma.

Metabolism

Calcium gluconate does not require hepatic metabolism for the release of Ca++ and is as effective as calcium chloride in treating ionic hypocalcemia in the absence of hepatic function.

Route of elimination

Renal (20%) - The amount excreted in the urine varies with degree of calcium absorption and whether there is excessive bone loss or failure of renal conservation. Fecal (80%) - Consists mainly of nonabsorbed calcium, with only a small amount of endogenous fecal calcium excreted.

Half life
Not Available
Clearance
Not Available
Toxicity

Infants : LDLo (Intramuscular ) : 10gm/kg ; Effects - Brain and coverings : meningeal changes Infants : TDLo ( Intramuscular ) : 143 mg/kg ; Effects - Dermatits Mouse: LD50 ( intravenous ) : 950mg/kg Mouse : LDLo (Oral ) : 10gm/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium gluconate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium gluconate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium gluconate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Alfacalcidol.Approved, Nutraceutical
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium gluconate.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium gluconate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium gluconate.Approved
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium gluconate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium gluconate.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium gluconate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium gluconate.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Calcium gluconate.Approved, Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcium Acetate.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium gluconate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium gluconate.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium gluconate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
CinoxacinCalcium gluconate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCalcium gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium gluconate.Approved, Investigational, Vet Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium gluconate.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Experimental
CymarinCalcium gluconate may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium gluconate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium gluconate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium gluconate.Approved
DeslanosideCalcium gluconate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium gluconate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium gluconate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium gluconate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium gluconate.Approved, Investigational
Dipotassium phosphateCalcium gluconate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium gluconate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium gluconate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium gluconate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium gluconate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium gluconate.Approved
EnoxacinCalcium gluconate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium gluconate.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium gluconate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium gluconate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium gluconate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium gluconate.Withdrawn
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium gluconate.Approved, Nutraceutical
FleroxacinCalcium gluconate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium gluconate.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium gluconate.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium gluconate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium gluconate.Investigational
GarenoxacinCalcium gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium gluconate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium gluconate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium gluconate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium gluconate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
Lanatoside CCalcium gluconate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium gluconate.Approved, Investigational
LevofloxacinCalcium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium gluconate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium gluconate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium gluconate.Approved
Lipoic AcidCalcium gluconate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LomefloxacinCalcium gluconate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium gluconate.Approved
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Calcium gluconate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Calcium gluconate.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium gluconate.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
MetildigoxinCalcium gluconate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium gluconate.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium gluconate.Approved, Investigational
MoxifloxacinCalcium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium gluconate.Investigational
Nalidixic AcidCalcium gluconate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium gluconate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium gluconate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium gluconate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium gluconate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium gluconate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium gluconate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate.Approved, Investigational
NorfloxacinCalcium gluconate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium gluconate.Approved
OfloxacinCalcium gluconate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium gluconate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium gluconate.Experimental, Investigational
OuabainCalcium gluconate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium gluconate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium gluconate.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium gluconate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium gluconate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium gluconate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCalcium gluconate may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium gluconate.Approved
Pipemidic acidCalcium gluconate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium gluconate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium gluconate.Withdrawn
ProscillaridinCalcium gluconate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium gluconate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium gluconate.Approved, Investigational
RosoxacinCalcium gluconate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium gluconate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium gluconate.Investigational
SitafloxacinCalcium gluconate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium gluconate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium gluconate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium gluconate.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium gluconate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium gluconate.Approved
TemafloxacinCalcium gluconate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium gluconate.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium gluconate.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium gluconate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium gluconate.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium gluconate.Approved, Investigational
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium gluconate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium gluconate.Approved, Investigational
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium gluconate.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium gluconate.Approved
TrovafloxacinCalcium gluconate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium gluconate.Investigational
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium gluconate.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium gluconate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium gluconate.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium gluconate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Martin TJ, Kang Y, Robertson KM, Virji MA, Marquez JM: Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function. Anesthesiology. 1990 Jul;73(1):62-5. [PubMed:2360741]
  2. Wikipedia [Link]
  3. DRUGS.COM [Link]
  4. Pubchem [Link]
  5. ChemIDplus [Link]
  6. DRUGS.COM [Link]
External Links
KEGG Compound
C08133
PubChem Compound
9290
PubChem Substance
347827907
ChemSpider
8932
ChEMBL
CHEMBL2106119
Wikipedia
Calcium_gluconate
ATC Codes
D11AX03 — Calcium gluconateA12AA03 — Calcium gluconate
AHFS Codes
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPaclitaxel-induced Neuropathy1
2CompletedSupportive CareArthralgia / Musculoskeletal Complications / Pain / Recurrent Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Not Yet RecruitingPreventionOHSS1
3Active Not RecruitingSupportive CareBone destruction / Prostate Cancer1
3CompletedDiagnosticBone destruction / Cancer, Breast1
3CompletedPreventionOvarian Hyperstimulation1
3CompletedSupportive CareChemotherapeutic Agent Toxicity / Colorectal Cancers / Neuropathy / Neurotoxicity1
3CompletedSupportive CareColorectal Cancers / Neurotoxicity1
3TerminatedSupportive CareNeuropathy / Pain / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
Not AvailableCompletedScreeningConotruncal Cardiac Defects / Heart Defects,Congenital / Parathyroid deficiency / Pulmonary Atresia / Pulmonary Valve Stenosis / Tetralogy Of Fallot1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous.465 meq/mL
Injection, solutionIntravenous94 mg/mL
Injection, solutionIntravenous98 mg/mL
LiquidIntravenous100 mg
SolutionIntravenous100 mg
SolutionIntramuscular; Intravenous100 mg
SolutionIntravenous.465 meq
SolutionIntravenous94 mg
SolutionIntravenous
TabletOral600 mg
TabletOral648 mg
TabletOral650 mg
LiquidOral
TabletOral
LiquidIntravenous10 %
LiquidIntravenous
DoucheVaginal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility44.2 mg/mLALOGPS
logP-2ALOGPS
logP-3.4ChemAxon
logS-0.99ALOGPS
pKa (Strongest Acidic)3.39ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area141.28 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity49.11 m3·mol-1ChemAxon
Polarizability16.62 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Monosaccharides / Secondary alcohols / Carboxylic acid salts / Polyols / Carboxylic acids / Organic calcium salts
show 6 more
Substituents
Gluconic_acid / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Hydroxy fatty acid / Hydroxy acid / Fatty acyl / Fatty acid / Monosaccharide / Carboxylic acid salt
show 14 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2015 09:51 / Updated on June 21, 2018 00:05